Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lymphoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib’s efficacy in the treatment and its place in the first-line treatment and...

Descripción completa

Detalles Bibliográficos
Autores principales: Katgı, Nuran, Çimen, Pınar, Akyol, Murat, Gürsoy, Pınar, Agüloğlu, Nurşin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Thoracic Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544624/
https://www.ncbi.nlm.nih.gov/pubmed/37485706
http://dx.doi.org/10.5152/ThoracResPract.2023.22200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544624/
https://www.ncbi.nlm.nih.gov/pubmed/37485706
http://dx.doi.org/10.5152/ThoracResPract.2023.22200

Ejemplares similares